Barclays PLC Raises Stake in Invivyd, Inc. (NASDAQ:IVVD)

Barclays PLC lifted its position in shares of Invivyd, Inc. (NASDAQ:IVVD) by 179.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 117,973 shares of the company’s stock after buying an additional 75,780 shares during the quarter. Barclays PLC owned approximately 0.10% of Invivyd worth $120,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. XTX Topco Ltd boosted its position in shares of Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after acquiring an additional 15,376 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd in the third quarter worth approximately $27,000. Marshall Wace LLP boosted its position in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after acquiring an additional 31,992 shares during the last quarter. State Street Corp boosted its position in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after acquiring an additional 53,499 shares during the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Terrance Mcguire sold 119,805 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the completion of the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at approximately $1,498,675.08. This represents a 3.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IVVD. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Morgan Stanley decreased their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. HC Wainwright cut their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Invivyd in a research report on Thursday, November 21st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Down 13.1 %

Shares of NASDAQ:IVVD opened at $0.46 on Thursday. The company has a market capitalization of $55.20 million, a price-to-earnings ratio of -0.24 and a beta of 0.64. The company has a 50 day moving average of $0.65 and a two-hundred day moving average of $0.92. Invivyd, Inc. has a 52-week low of $0.40 and a 52-week high of $5.20.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.